16 Non-Small Cell Lung Cancer Clinical Trials in Duarte, CA (2026)

Q: How do I join a clinical trial in Duarte?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you.

Recruiting Non-Small Cell Lung Cancer Studies in Duarte

NCT04928846Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Duarte, CAPHASE3768 participantsAbbVie

View Study Details

NCT05005403Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Duarte, CAPHASE1694 participantsAbbVie

View Study Details

NCT06128551Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors....

Duarte, CAPHASE1534 participantsRevolution Medicines, Inc.

View Study Details

NCT07155187Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease ac...

Duarte, CAPHASE2490 participantsAbbVie

View Study Details

NCT06667076Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth f...

Duarte, CAPHASE2480 participantsJanssen Research & Development, LLC

View Study Details

NCT04165070Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-04...

Duarte, CAPHASE1450 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Duarte, CAPHASE1430 participantsBayer

View Study Details

NCT07291037Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metast...

Duarte, CAPHASE3400 participantsAstraZeneca

View Study Details

NCT06043817Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cel...

Duarte, CAPHASE1345 participantsAntares Therapeutics, Inc

View Study Details

NCT06686771Recruiting

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study ...

Duarte, CAPHASE3320 participantsCanadian Cancer Trials Group

View Study Details

NCT04686305Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-s...

Duarte, CAPHASE1304 participantsAstraZeneca

View Study Details

NCT07277413Recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with met...

Duarte, CAPHASE1260 participantsIDEAYA Biosciences

View Study Details

NCT05967689Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring...

Duarte, CAPHASE2220 participantsTaiho Oncology, Inc.

View Study Details

NCT06218914Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors....

Duarte, CAPHASE1108 participantsAstraZeneca

View Study Details

NCT04302025Recruiting

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors tha...

Duarte, CAPHASE299 participantsGenentech, Inc.

View Study Details

NCT05877599Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors....

Duarte, CAPHASE145 participantsAstraZeneca

View Study Details

About Non-Small Cell Lung Cancer Clinical Trials in Duarte

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Treatment has been transformed by targeted therapies and immunotherapy based on specific genetic markers.

There are currently 16 non-small cell lung cancer clinical trials recruiting participants in Duarte, CA. These studies are seeking a combined 5,947 participants. Research is being sponsored by AbbVie, Revolution Medicines, Inc., Janssen Research & Development, LLC and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Non-Small Cell Lung Cancer Clinical Trials in Duarte — FAQ

Are there non-small cell lung cancer clinical trials in Duarte?

Yes, there are 16 non-small cell lung cancer clinical trials currently recruiting in Duarte, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Duarte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.

Are clinical trials in Duarte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.

What non-small cell lung cancer treatments are being tested?

The 16 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for non-small cell lung cancer.

Data updated October 17, 2026 from ClinicalTrials.gov